7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Cell circuits as targets and biomarkers for liver disease and cancer prevention (HEPCIR)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Chronic liver diseases such as liver cirrhosis and hepatocellular carcinoma (HCC) are major challenges for global health. HCC is the second leading and fastest rising cause of cancer death worldwide. The limited availability of therapeutic options reflects our poor understanding of the molecular and clinical mechanisms involved in progression of liver disease. Chronic hepatitis C virus (HCV) infec ...
Voir le projet
2
Participants partenaires
TERMINÉ
Integrating Epidemiology and Experimental Biology to Improve Risk Assessment of Exposure to Mixtures of Endocrine Disruptive Compounds (EDC-MixRisk)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2019,
A large body of evidence supports associations between exposure to anthropogenic chemicals and endocrine disruptive effects, leading to disorders in humans and wildlife. Based on the scientific documentation it is beyond doubt that endocrine disrupting chemicals (EDCs) are of concern and need to be handled according to the risks they pose, as single chemicals or as mixtures. To develop chemical ri ...
Voir le projet
14
Participants partenaires
TERMINÉ
Validating predictive models of radiotherapy toxicity to improve quality-of-life and reduce side-effects in cancer survivors (REQUITE)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
Long-term side-effects of radiotherapy impact on the quality-of-life (QoL) of cancer survivors. These side-effects could be reduced if predicted in advance. Previous work identified clinical and biological predictors but a major, coordinated approach is needed to validate them so they can be used clinically. The EU has ~17.8 million people living with a prior diagnosis of cancer of whom ~7 million ...
Voir le projet
15
Participants partenaires
TERMINÉ
Global initiative on gene-environment interaction on diabetes/obesity risk (InterConnect)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
The overall goal of InterConnect is to establish a global network that will facilitate the co-ordination of population research on the interaction between genetic and environmental factors in the aetiology of obesity and diabetes. We aim to establish mechanisms for identification and classification of studies and the data that they hold and create a forum for harmonization of methods as a foundati ...
Voir le projet
12
Participants partenaires
TERMINÉ
IMAging GEnetics for MENtal Disorders (IMAGEMEND)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
"Mental disorders are leading causes of disability, absence from work and premature retirement in Europe. While magnetic resonance imaging (MRI) facilities are broadly available and a vast research literature exists, few neuroimaging applications have reached clinical practice in psychiatry. A major problem is that mental illnesses are currently diagnosed as discrete entities defined clinically. I ...
Voir le projet
15
Participants partenaires
TERMINÉ
Patient-centered palliative care pathways in advanced cancer and chronic disease (INSUP-C)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,
Integrated delivery systems of care, e.g. networks of health organizations and professionals who work together to coordinate services to meet their patients’ needs, are an important way of linking fragmented services and maximizing system efficiency and seamlessness of patient transition. Research increasingly shows that patients with advanced cancer and advanced chronic disease are treated well ...
Voir le projet
11
Participants partenaires
TERMINÉ
Genomic predictors and oncogenic drivers in hepatocellular carcinoma (HEPTROMIC)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,
"Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers, and is a major health problem. Its incidence is growing and with more than 700,000 annual cases worldwide -50,000 in Europe-, it is the 3rd cause of cancer-related mortality. Most patients are diagnosed at advanced stages with dismal survival rates lower than 1 year, even after sorafenib, the sole systemic therapy availab ...
Voir le projet